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Abstract
Brucella species cause brucellosis in humans and animals, a zoonosis that can manifest not
only as acute or chronic diseases but also as silent infections persisting throughout life
with recurrences potentially occurring after several decades. In vitro and in vivo methods
have been developed to evaluate the bacteriostatic and bactericidal activity of antibiotics
against Brucella sp. Especially eukaryotic cells and animal models have been used to eval‐
uate the ability of antibiotics, alone or in combination, to eradicate these bacteria from
their intracellular reservoir. Although treatment recommendations have been established
for common clinical forms of brucellosis, optimized therapeutic alternatives are still need‐
ed for severe forms of the disease, and for infections occurring in young children and
pregnant women. Moreover, acquired resistance to first-line treatments of brucellosis is a
current concern. This chapter will summarize current knowledge on in vitro and in vivo
interactions between Brucella species and antibiotics and new therapeutic strategies that
have been evaluated.
Keywords: Brucella, brucellosis, antibiotic susceptibility testing, antibiotic resistance,
treatment
1. Introduction
Most Brucella species are highly infectious in humans and thus are considered class 3 biological
agents [1–3] and potential biological threat agents by the CDC (class B) [4,5]. Because of a high
risk of human infections, especially through inhalation of infectious aerosols, the Brucella
cultures should be handled in a biosafety level 3 laboratory. Also, in many countries, detention
of these pathogens is now subject to strict regulations. The clinical symptoms of brucellosis
are often unspecific. Therefore, the diagnosis may be delayed, especially in geographic areas
where the disease is rare and thus often not evoked by physicians in febrile patients. A definite
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diagnosis of brucellosis relies on isolation of Brucella sp. from infected patients, mainly from
blood samples during the first few weeks following the onset of symptoms. Serological
methods lack specificity, and only represent a stopgap for brucellosis diagnosis. PCR-based
techniques are useful to detect Brucella DNA in clinical samples, especially in patients with
suppurated secondary locations. A specific antibiotic therapy should be started as soon as
possible to avoid severe complications (including neurological and cardiac involvement), and
evolution to a chronic debilitating disease. However, current treatment alternatives are still
scarce in adult patients, and even more limited in young children and pregnant women.
Although rarely fatal, brucellosis remains a major public health problem worldwide, and a
significant economic burden in livestock because of its abortive nature. This chapter will
summarize current knowledge on antibiotic susceptibilities of Brucella species and treatment
alternatives for human brucellosis. In the first part of this chapter, experimental models
currently used for the evaluation of the activity of antibiotics against Brucella species will be
presented, including in vitro models with or without eukaryotic cells, and animal models. The
results obtained in these experimental models will be summarized and tentatively correlated
with each other and with current knowledge on the clinical efficacy of antibiotics in brucellosis
patients. The available data on antibiotic resistances in Brucella species will be presented, with
their potential impact in clinical situations. The second part of this chapter will present current
strategies for the development of new therapeutic alternatives for human brucellosis. These
may include the development of new drugs inhibiting the intracellular growth of Brucella sp.,
reducing the virulence of this pathogen or enhancing the host response to Brucella infection.
2. Experimental models for evaluation of the activity of antibiotics against
Brucella spp.
Routine antibiotic susceptibility testing (AST) of Brucella sp. is not currently advocated because
of lack of acquired resistances to clinically useful antibiotics and a high risk of laboratory-
acquired brucellosis [6,7]. Three types of experimental models have been used to assess the
activities of antibiotics against Brucella sp.: AST in cell-free liquid or solid media (minimum
inhibitory concentration (MICs)), AST in Brucella-infected eukaryotic cell models, and
Brucella-infected animal models. We will summarize data obtained in these three models and
their respective predictive value of the clinical efficacy of antibiotics in brucellosis patients.
2.1. AST in axenic media
2.1.1. Bacteriostatic activity by class of antibiotics
Current reference methods for the in vitro determination of the minimum inhibitory concen‐
tration (MIC) of antibiotics against bacteria in axenic media do not apply to the fastidious and
slow growth of Brucella species. The method recommended by the Clinical and Laboratory
Standards Institute (CLSI) includes the use of Brucella medium (pH 7.1), inoculated with a 0.5
McFarland standard inoculum, and an incubation at 35 ± 2°C in aerobic atmosphere for 48 h
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before reading MICs [8]. An incubation in 5% CO2-enriched atmosphere may be required for
some Brucella strains, but this usually increases MIC levels [9–11]. Using this method, sus‐
ceptibility breakpoints for Brucella are ≤ 8 mg/L for streptomycin; ≤ 4 mg/L for gentamicin; ≤ 1
mg/L for tetracycline, doxycycline, and rifampicin; and ≤ 2/38 mg/L for the combination of
trimethoprim (TMP) plus sulfamethoxazole (SMX) (i.e., cotrimoxazole).
In the literature, however, the multiplicity of methods used for MIC determination for Brucella
strains shows a lack of standardization (Tables 1 and 2). MICs were determined using either
the Kirby–Bauer agar disk diffusion method, the E-test strip method, a broth dilution or
microdilution method, or the agar dilution method. Culture media have included Brucella
broth, Mueller Hinton agar with or without 5% sheep blood, Mueller Hinton broth supple‐
mented with 1% polyvitex with or without 1% hemoglobin, Trypticase soy broth, and Iso-
Sensitest® Agar (Oxoid, CM47L). The tested bacterial inoculum was expressed in McFarland
standard, cfu/mL, or cfu per spot, often without any correspondence between units, and it
varied between studies (e.g., 105–106 cfu/mL, 0.5–1 McFarland). The incubation atmosphere
varied from 35°C to 37°C, with 0%–10% CO2. The incubation time before reading MICs varied
from 24 h to 48 h. Obviously, all these parameters may change MIC levels. Several studies have
shown that a high bacterial load and a low pH of the culture medium increase MICs by two
to four times or even more [9,11–15].
A first interesting finding is the variability in susceptibility to beta-lactams among Brucella
strains (Table 2). In cell-free media, MICs to ampicillin varied from 0.02 mg/L to 8 mg/L, with
MIC90 of 2–4 mg/L [9,16–19]. For ceftriaxone, a third-generation cephalosporin, MICs varied
from 0.064 mg/L to 4 mg/L, with MIC90 of 0.5–1 mg/L [20–23]. For thienamycin, a carbapenem
compound, MICs varied from 0.1 mg/L to 2 mg/L, with an MIC90 of 2 mg/L [24]. These
variations were also observed for other beta-lactams tested, although Brucella species were less
susceptible to aztreonam [20]. Because heterogeneity in MICs was observed whatever the
methodology used, they may represent true variations in genetic backgrounds among Brucella
strains. However, beta-lactamases have never been characterized in these species, neither
variations in penicillin-binding proteins (PBP).
The tetracyclines display the lowest MICs against Brucella spp. in cell-free media (Table 1).
However, these MICs greatly vary according to the methodology used. Doxycycline, which is
currently recommended as first-line treatment of brucellosis, displayed MICs ranging from
0.6 to 0.25 mg/L (MIC90 of 0.12–0.25 mg/L), when using the agar dilution method with either
the CM47L medium or Mueller Hinton agar, supplemented with hemoglobin and polyvitex
(1% each) [23,25]. The broth microdilution method gave MICs ranging from 0.01 to 0.5 mg/L
(MIC90 of 0.06–0.3 mg/L), using various media and incubation conditions [9,10,19]. However,
MICs up to 8 mg/L were reported in a Turkish study of 43 human strains of B. melitensis [11].
The only significant difference in the methodology might have been the use of a high bacterial
inoculum (i.e., 105–106 cfu per well). The E-test method, using sheep blood-supplemented
Mueller Hinton agar and a 0.5 McFarland standard inoculum, gave MICs ranging from 0.023
to 0.5 mg/L (MIC90 of 0.064–0.38 mg/L) [21,22,26–28]. Using the E-test method, much higher
MICs ranging from 8 to 32 mg/L were recently reported for 19 Chinese strains of B. melitensis,
although the incubation time before the MIC reading was only 24 h [17]. Tigecycline was no
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more effective than doxycycline, with MICs ranging from 0.019 to 0.5 mg/L using the E-test
method [26,27,29].
Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Aminoglycosides
Streptomycin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 2.5 0.15->100 [9]
Israel/H Bru, 31,1978–82
Agar dilution (CM47L, 104/mL,
10%, 37°C, 48 h) 2 0.125-4 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 105/mL,
10%, 37°C, 48 h) 8 0.06-8 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 106/mL,
10%, 37°C, 48 h) 8 0.25-8 [12]
Spain/H Bm, 95,1980–84
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.5 0.12-1 [23]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 4 1-4 [18]
Saudi Arabia Bm, 47,(1989)
Broth dilution (BB,5 ×
105cfu/mL, 0%, 35°C, 48 h) 2.5 0.15-5 [13]
Israel/H Bm, 86,(1991)
Broth microdilution (BB, 5 ×
105cfu/mL,5%,37°C,48 h) 3.1 NA [33]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
7,105-6cfu,0%,35°C,48 h) 2 0.25-8 [11]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
5,105-6cfu,0%,35°C,48 h) 128 8-256 [11]
Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 4 0.1-4 [30]
Spain/H Bm, 160,1997
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 8 4-16 [25]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 2 0.5-2 [19]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 2 0.125-4 [16]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 2 0.125-3 [22]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Syria Bm, 100,2004–07
Broth microdilution (BB/7, 5 ×
106 cfu/mL,37°C, 48 h) >128 64->128 [15]
Syria Bm, 100,2004–07
Broth microdilution (BB/5, 5 ×
106 cfu/mL,37°C, 48 h) >128 >128 [15]
Turkey/H Bru, 56,2008–09
E-test (SB-MH, 0.5 McFd, 0%,
35°C, 48 h) 1 0.064-1.5 [27]
Turkey/H Bm, 73,2009–11
E-test (SB-MH, 0.5 McFd, NA,
37°C, 48 h) 1 0.5-1.5 [26]
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C,48 h) 1 0.064-1.5 [29]
US/H Bru, 39,(2010)
Broth microdilution (BB, NA,
0%, 35°C, 48 h) 2 1-8 [10]
Bru, 39,
(2010)
Broth microdilution (BB, NA,
5%, 35°C, 48 h) 4 2-16 [10]
Gentamicin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 0.3 0.02-2.5 [9]
Israel/H Bru, 31,1978–82
Agar dilution (CM47L, 104/mL,
10%, 37°C, 48 h) 0.25 0.03-0.25 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 105/mL,
10%, 37°C, 48 h) 1 0.03-1 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 106/mL,
10%, 37°C, 48 h) 2 0.03-2 [12]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 1 0.25-2 [18]
Saudi Arabia Bm, 116,(1995)
Broth dilution (MH,105-6cfu/mL,
5%, 35°C, 48 h) 0.5 <0.25-0.5 [31]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 1 0.5-2 [19]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 2 0.03-1.5 [16]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 1 0.094-3 [22]
Peru/H Bm, 48,2000–06
E-test (SB-MH, 0.5 McFd, NA,
NA, 48 h) 0.25 0.032-0.25 [28]
Antibiotic Susceptibility Testing of Brucella Species - Old and New Drugs
http://dx.doi.org/10.5772/61706
129
Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C,48 h) 0.5 0.064-0.75 [29]
US/H Bru, 39,(2010)
Broth microdilution (BB, ND,
0%, 35°C, 48 h) 2 0.5-2 [10]
Bru, 39,
(2010)
Broth microdilution (BB, ND,
5%, 35°C, 48 h) 4 0.5-8 [10]
China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 0.75 0.5-0.75 [17]
Tobramycin US-Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 2 0.5-4 [18]
Kanamycin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 2.5 0.02-5 [9]
Amikacin US-Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 4 1-4 [18]
China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 12 4-12 [17]
Tetracyclines
Tetracycline US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 0.04 0.001-0.15 [9]
Israel/H Bru, 31,1978–82
Agar dilution (CM47L, 104/mL,
10%, 37°C, 48 h) 0.25 ≤0.06-0.5 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 105/mL,
10%, 37°C, 48 h) 0.5 ≤0.06-0.5 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 106/mL,
10%, 37°C, 48 h) 1 ≤0.06-2 [12]
Spain/H Bm, 95,1980–84
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.25 0.6-0.25 [23]
Spain/H Bm, 98,(1982)
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.39 0.1-0.5 [24]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 0.25 ≤0.13-0.25 [18]
Spain/H Bm, 358,1987–89
Agar dilution (CM471, 105cfu/
spot, 0%, 37°C, 48 h) 0.25 0.06-0.5 [32]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Saudi Arabia Bm, 47,(1989)
Broth dilution (BB,5 ×
105cfu/mL, 0%, 35°C, 48 h) 0.04 0.001-0.6 [13]
Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP, 104cfu/
spot, 10%, 35°C, 48 h) 0.2 0.01-0.2 [30]
Saudi Arabia Bm, 116,(1995)
Broth dilution (MH, 105-6cfu/mL,
5%, 35°C, 48 h) 0.5 <0.25-0.5 [31]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 0.5 0.03-1.5 [16]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 0.25 0.125-0.5 [19]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 0.19 0.023-0.75 [22]
Syria Bm, 100,2004–07
Broth microdilution (BB/7, 5 ×
106 cfu/mL, 37°C, 48 h) 16 0.25-16 [15]
Syria Bm, 100,2004–07
Broth microdilution (BB/5, 5 ×
106 cfu/mL, 37°C, 48 h) 16 0.25-16 [15]
US/H Bru, 39,(2010)
Broth microdilution (BB, ND,
0%, 35°C, 48 h) 0.25 0.06-0.5 [10]
Bru, 39,
(2010)
Broth microdilution (BB, ND,
5%, 35°C, 48 h) 0.25 0.03-0.5 [10]
Doxycycline US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 0.3 0.01-0.3 [9]
Spain/H Bm, 95,1980–84
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.12 0.6-0.25 [23]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
7,105-6cfu,0%, 35°C,48 h) <0.125 <0.125-8 [11]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
5,105-6cfu,0%, 35°C,48 h) 2 <0.125-8 [11]
Spain/H Bm, 160,1997
Agar dilution (MH-HP, 104cfu/
spot, 10%, 35°C,48 h) 0.25 0.12-0.25 [25]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 0.25 0.063-0.5 [19]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 0.25 0.016-0.5 [22]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Peru/H Bm, 48,2000–06
E-test (SB-MH, 0.5 McFd, NA,
NA, 48 h) 0.38 0.032-0.5 [28]
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C,48 h) 0.125 0.016-0.19 [29]
Syria Bm, 100,2004–07
Broth microdilution (BB/7, 5 ×
106 cfu/mL, 37°C, 48 h) 16 0.5-16 [15]
Syria Bm, 100,2004–07
Broth microdilution (BB/5, 5 ×
106 cfu/mL, 37°C, 48 h) 8 0.5-8 [15]
Italy/H Bru, 20,2005–06
E-test (SB-MH, 0.5 McFd, 5%,
37°C, 48 h) ND 0.06-0.125 [21]
Turkey/H Bru, 56,2008–09
E-test (SB-MH, 0.5 McFd, 0%,
35°C, 48 h) 0.064 0.023-0.125 [27]
Turkey/H Bm, 73,2009–11
E-test (SB-MH, 0.5 McFd, NA,
37°C, 48 h) 0.094 0.023-0.19 [26]
US/H Bru, 39,(2010)
Broth microdilution (BB, ND,
0%, 35°C, 48 h) 0.25 0.06-0.5 [10]
Bru, 39,
(2010)
Broth microdilution (BB, ND,
5%, 35°C, 48 h) 0.5 0.03-1 [10]
China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 32 8-32 [17]
Minocycline US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 0.3 0.01-1.25 [9]
Israel/H Bm, 86,(1991)
Broth microdilution (BB, 5 ×
105cfu/mL, 5%, 37°C, 48 h) 0.4 NA [33]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 0.125 0.063-0.25 [19]
Tigecycline Turkey/H Bru, 56,2008–09
E-test (SB-MH, 0.5 McFd, 0%,
35°C, 48 h) 0.094 0.019-0.25 [27]
Turkey/H Bm, 73,2009–11
E-test (SB-MH, 0.5 McFd, NA,
37°C, 48 h) 0.125 0.047-0.19 [26]
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C, 48 h) 0.094 0.023-0.5 [29]
Turkey/H Bm, 38,(2010) E-test (SB, NA, NA, 35°C, 48 h) 0.5 0.032-0.5 [76]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Turkey/H Bm, 38,(2010) E-test (BA, NA, NA, 35°C, 48 h) 1 0.0125-1 [76]
Rifampin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 1.25 0.02-12.5 [9]
Spain/H Bm, 98,(1982)
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.5 0.06-1 [24]
Spain/H Bm, 95,1980–84
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 2 0.12-4 [23]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB, 5 ×
105cfu/mL, 6%, 35°C, 48 h) 1 0.06-1 [18]
Saudi Arabia Bm, 47,(1989)
Broth dilution (BB, 5 ×
105cfu/mL, 0%, 35°C, 48 h) 1.25 0.02-2.5 [13]
Israel/H Bm, 86,(1991)
Broth microdilution (BB, 5 ×
105cfu/mL, 5%, 37°C, 48 h) 4 NA [33]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
7,105-6cfu, 0%, 35°C, 48 h) 2 1-32 [11]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
5,105-6cfu, 0%, 35°C, 48 h) 1 <0.125-1 [11]
Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP, 104cfu/
spot, 10%, 35°C, 48 h) 1 0.1-4 [30]
Saudi Arabia Bm, 116,(1995)
Broth dilution (MH, 105-6cfu/mL,
5%, 35°C, 48 h) 1 0.25-1 [31]
Spain/H Bm, 160,1997
Agar dilution (MH-HP, 104cfu/
spot, 10%, 35°C, 48 h) 1 0.5-1 [25]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 2 0.5-4 [19]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 1 0.09-1.5 [16]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 4 0.25-6 [22]
Peru/H Bm, 48,2000–06
E-test (SB-MH, 0.5 McFd, NA,
NA, 48 h) 0.75 0.19-1 [28]
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C,48 h) 1.5 0.064-3 [29]
Antibiotic Susceptibility Testing of Brucella Species - Old and New Drugs
http://dx.doi.org/10.5772/61706
133
Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Syria Bm, 100,2004–07
Broth microdilution (BB/7, 5 ×
106 cfu/mL,37°C, 48 h) 64 2-64 [15]
Syria Bm, 100,2004–07
Broth microdilution (BB/5, 5 ×
106 cfu/mL,37°C, 48 h) 64 2-64 [15]
Italy/H Bru, 20,2005–06
E-test (SB-MH, 0.5 McFd, 5%,
37°C, 48 h) ND 0.75-2 [21]
Turkey/H Bru, 56,2008–09
E-test (SB-MH, 0.5 McFd, 0%,
35°C, 48 h) 2 0.5-2 [27]
Turkey/H Bm, 73,2009–11
E-test (SB-MH, 0.5 McFd, NA,
37°C, 48 h) 2 0.38-3 [26]
US/H Bru, 39,(2010)
Broth microdilution (BB, ND,
0%, 35°C, 48 h) 2 0.25-2 [10]
Bru, 39,
(2010)
Broth microdilution (BB, ND,
5%, 35°C, 48 h) 2 0.25->8 [10]
China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 2 0.06-2 [17]
Rifapentine Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP, 104cfu/
spot, 10%, 35°C, 48 h) 1 0.2-4 [30]
NA, data not available; Bm, B. melitensis; Bab, B. abortus; Bru, Brucella sp.
£Studies have been classified according to the period of isolation of the studied Brucella strains (e.g., 2010–12) and the date
of the corresponding publication (e.g., (1993)) when the latter was unavailable.
$Method: Kirby–Bauer disk diffusion method (Kirby–Bauer); E-test strip method (E-test);
Medium: Mueller Hinton agar with 5% sheep blood (SB-MH) or unspecified percentage and type of blood (BA-MH); 5%
sheep blood agar (SB); Brucella broth (BB); Brucella agar (BA); Trypticase soy broth (TSB); Iso-Sensitest® Agar CM47L
(CM47L); Mueller Hinton broth supplemented with 1% polyvitex with (HP) or without (P) 1% hemoglobin, at pH 7 (/7)
or pH 5 (/5); The bacterial inoculum used for antibiotic susceptibility testing is specified in cfu/mL or according to
McFarland standards (McFd). Host: human (H), cattle (C), unspecified or various animals (A).
Table 1. Antibiotic susceptibilities of Brucella sp. to aminoglycosides, tetracyclines, and rifampin, as determined in cell-
free media.
Rifampicin is the second most active compound against Brucella sp. in cell-free medium (Table
1). MICs ranged from 0.06 to 4 mg/L with the agar dilution method [23–25,30], 0.06 to 4 mg/L
with the broth dilution method [10,11,13,18,19,31], and 0.06 to 6 mg/L with the E-test method
[16,17,21,22,26–29]. Higher MICs (up to 12.5 mg/L) were reported in one study using Brucella
broth and a 10% CO2 atmosphere incubation [9]. Rifampicin MICs were lower at acidic pH [11],
but higher at increasing concentrations of CO2 [10,11].
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The aminoglycosides are also highly active in vitro against Brucella sp. (Table 1). Streptomy‐
cin has long been used as first-line treatment of  brucellosis,  whereas gentamicin is  now
used  in  most  countries  because  the  former  antibiotic  is  no  longer  available.  MICs  to
streptomycin varied from 0.12 to 4 mg/L with the agar dilution method [23,30], although
a more recent study from Spain reported higher MIC levels (4–16 mg/L) for 160 human
strains of B. melitensis [25]. MICs varied from 0.1 to 16 mg/L with the broth dilution method
[10,11,13,18,19,25].  An acidic  pH of  the  broth  medium and/or  an incubation in  5%–10%
CO2-enriched atmosphere were associated with higher MICs [9–11]. Higher MIC levels (≥256
mg/L) were, however, occasionally reported with this technique [9,11]. MICs ranged from
0.06  to  4  mg/L with  the  E-test  method [16,22,27,29].  Gentamicin  displayed lower  MICs,
ranging from 0.02 to 2.5 mg/L [9,10,18,31] with the broth dilution method, and 0.03 to 3
mg/L with the E-test method [16,17,22,28,29].
The combination of trimethoprim (TMP) and sulfamethoxazole (SMX) was usually tested at a
ratio of 1:19, and only TMP MICs were reported (Table 2). These varied from 0.06 to 4 mg/L
with the agar dilution method [23,30], 0.006 to 4 mg/L with the broth microdilution method
[10,18,31], and 0.06 to 1.5 mg/L with the E-test method [16,21,22,26–29]. Similar MIC ranges
(0.8–3.2 mg/L) were obtained when using TMP/SMX at a ratio of 1:5 [17]. In contrast, higher
MICs (5–25 mg/L of TMP) were reported in a study from Saudi Arabia [13], using a broth
dilution method with high-volume (5 mL) medium culture and a high bacterial inoculum (2.5
× 106 cfu per test).
Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
β-lactams
Penicillin G US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 25 0.3->100 [9]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 4 0.25-8 [18]
Ampicillin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 2.5 0.02-5 [9]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 4 0.25-8 [18]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 2 0.09-3 [16]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 4 0.125-4 [19]
China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 2 1.5-2 [17]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Carbenicillin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 50 0.6->100 [9]
Cephalothin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 100 0.3->100 [9]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 32 1-64 [18]
Cefoxitine Spain/H Bm, 98,(1982)
Agar dilution (CM47L, 105 cfu/
spot, 0%, 37°C, 48 h) 64 8-128 [24]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 16 2-16 [18]
Cefuroxime Spain/H Bm, 83,(1986)
Agar dilution (CM47L, 105 cfu/
spot, 0%, 37°C, 48 h) 32 8-64 [20]
Ceftizoxime Spain/H Bm, 83,(1986)
Agar dilution (CM47L, 105 cfu/
spot, 0%, 37°C, 48 h) 1 0.5-1 [20]
Cefoperazone US-Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 16 ≤1-16 [18]
Spain/H Bm, 83,(1986)
Agar dilution (CM47L, 105 cfu/
spot, 0%, 37°C, 48 h) 32 4-64 [20]
Cefotaxime US-Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL, 6%,35°C,48 h) 2 ≤0.5-4 [18]
Spain/H Bm, 83,(1986)
Agar dilution (CM47L, 105 cfu/
spot, 0%, 37°C, 48 h) 2 ≤0.5-2 [20]
Ceftriaxone Spain/H Bm, 95,1980–84
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.5 0.12-1 [23]
Spain/H Bm, 83,(1986)
Agar dilution (CM47L, 105 cfu/
spot, 0%, 37°C, 48 h) 1 ≤0.25-1 [20]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 1 0.064-4 [22]
Italy/H Bru, 20,2005–06
E-test (SB-MH, 0.5 McFd, 5%,
37°C, 48 h) NA 0.064-0.38 [21]
Ceftazidime China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 8 2-8 [17]
Moxalactam US-Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL, 6%,35°C,48 h) 16 1-16 [18]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Spain/H Bm, 83,(1986)
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 16 4-16 [20]
Aztreonam Spain/H Bm, 83,(1986)
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) >256 64->256 [20]
Thienamycin Spain/H Bm, 98,(1982)
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 2 0.1-2 [24]
TMP/SMX* Spain/H Bm, 98,(1982)
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 6.25 0.39-6.25 [24]*
Spain/H Bm, 95,1980–84
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.25 0.06-0.5 [23]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 1 ≤0.25-1 [18]
Saudi Arabia Bm, 47,(1989)
Broth dilution (BB,5 × 105cfu/mL,
0%, 35°C, 48 h) 5 5-25 [13]
Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 4 0.1-4 [30]
Saudi Arabia Bm, 116,(1995)
Broth dilution (MH, 105-6cfu/mL,
5%, 35°C, 48 h) 1 <0.25-1 [31]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 0.75 0.032-1.5 [16]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 0.19 0.006-0.75 [22]
Peru/H Bm, 48,2000–06
E-test (SB-MH, 0.5 McFd, NA,
NA, 48 h) 0.15 0.012-0.64 [28]
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C,48 h) 0.094 0.016-0.125 [29]
Italy/H Bru, 20,2005–06
E-test (SB-MH, 0.5 McFd, 5%,
37°C, 48 h) ND 0.012/0.064 [21]
Turkey/H Bru, 56,2008–09
E-test (SB-MH, 0.5 McFd, 0%,
35°C, 48 h) 0.125 0.064-0.25 [27]
Turkey/H Bm, 73,2009–11
E-test (SB-MH, 0.5 McFd, NA,
37°C, 48 h) 0.19 0.016-0.5 [26]
China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 3.2 0.8-3.2 [17]*
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
US/H Bru, 39,(2010)
Broth microdilution (BB, ND,
0%, 35°C, 48 h) 2 0.25-2 [10]
Bru, 39,
(2010)
Broth microdilution (BB, ND,
5%, 35°C, 48 h) 2 0.25-4 [10]
Chloramphenicol US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 0.3->100 [9]
Israel/H Bru, 31,1978–82
Agar dilution (CM47L, 104/mL,
10%, 37°C, 48 h) 2 0.125-4 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 105/mL,
10%, 37°C, 48 h) 4 0.06-4 [12]
Bru, 31,
1978–82
Agar dilution (CM47L, 106/mL,
10%, 37°C, 48 h) 8 0.06-8 [12]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 2 0.25-4 [18]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 5 0.15-12.5 [19]
Macrolides and
azalides
Erythromycin US/HA Bru, 27,(1970)
Broth microdilution (BB, NA,
10%, 37°C, 48 h) 0.6 0.02-2.5 [9]
US-
Mexico/HA
Bru, 15,
(1986)
Broth microdilution (TSB,5 ×
105cfu/mL,6%,35°C,48 h) 8 0.5-8 [18]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
7,105-6cfu,0%,35°C,48 h) 128 0.5-256 [11]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
5,105-6cfu,0%,35°C,48 h) >256 32->256 [11]
Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 16 0.2-16 [30]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 4 0.5-8 [16]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 2 1-4 [19]
Roxithromycin Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 16 0.1-32 [30]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Dirithromycin Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 16 0.5-16 [30]
Clarithromycin Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 8 0.06-8 [30]
Azithromycin Spain/H Bm, 358,1987–89
Agar dilution (CM471, 105cfu/
spot, 0%, 37°C, 48 h) 1 0.03-2 [32]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
7,105-6cfu,0%,35°C,48 h) 1 <0.125-4 [11]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
5,105-6cfu,0%,35°C,48 h) >256 16->256 [11]
Spain/HA Bru, 62,(1993)
Agar dilution (MH-HP, 104cfu/
spot, 10%,35°C, 48 h) 2 0.1-4 [30]
Saudi Arabia Bm, 116,(1995)
Broth dilution (MH,105-6cfu/mL,
5%, 35°C, 48 h) 0.5 <0.25-2 [31]
Peru/H Bm, 48,2000–06
E-test (SB-MH, 0.5 McFd, NA,
NA, 48 h) 0.5 0.064-0.5 [28]
Turkey/H Bm, 73,2009–11
E-test (SB-MH, 0.5 McFd, NA,
37°C, 48 h) 8 0.75-16 [26]
Fluoroquinolones
Norfloxacin Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 3 0.125-4 [16]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 8 4-16 [19]
Ofloxacin Saudi Arabia Bm, 47,(1989)
Broth dilution (BB,5 × 105cfu/mL,
0%, 35°C, 48 h) 0.02 0.02-0.3 [13]
Israel/H Bm, 86,(1991)
Broth microdilution (BB, 5 ×
105cfu/mL,5%,37°C,48 h) 2.5 ND [33]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
7,105-6cfu,0%,35°C,48 h) 1 <0.125-4 [11]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
5,105-6cfu,0%,35°C,48 h) >16 4->16 [11]
Spain/H Bm, 160,1997
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 2 1-2 [25]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 2 0.5-2 [19]
Levofloxacin Spain/H Bm, 160,1997
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 0.5 0.5 [25]
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 0.5 0.06-0.75 [16]
China/H Bm, 19,2010–12
E-test (BA-MH, 0.5 McFd, 5%,
35°C, 24 h) 8 2-8 [17]
Ciprofloxacin Spain/H Bm, 95,1980–84
Agar dilution (CM47L, 105cfu/
spot, 0%, 37°C, 48 h) 0.5 0.12-0.5 [23]
Saudi Arabia Bm, 47,(1989)
Broth dilution (BB,5 × 105cfu/mL,
0%, 35°C, 48 h) 1.25 1.25-2.5 [13]
Israel/H Bm, 86,(1991)
Broth microdilution (BB,5 ×
105cfu/mL,5%,37°C,48 h) 0.8 NA [33]
Spain/H Bm, 34,(1991)
Agar dilution (MH-HP/7,103cfu/
spot,10%,35°C,48 h) 0.5 0.25-0.5 [14]
Spain/H Bm, 34,(1991)
Agar dilution (MH-HP/5,103cfu/
spot,10%,35°C,48 h) 1 0.5-1 [14]
Spain/H Bm, 34,(1991)
Agar dilution (MH-HP/7,104cfu/
spot,10%,35°C,48 h) 0.5 0.25-0.5 [14]
Spain/H Bm, 34,(1991)
Agar dilution (MH-HP/5,104cfu/
spot,10%,35°C,48 h) 1 0.5-1 [14]
Spain/H Bm, 34,(1991)
Agar dilution (MH-HP/7,106cfu/
spot,10%,35°C,48 h) 1 0.5-1 [14]
Spain/H Bm, 34,(1991)
Agar dilution (MH-HP/5,106cfu/
spot,10%,35°C,48 h) 2 1-2 [14]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
7,105-6cfu,0%,35°C,48 h) 2 <0.125-8 [11]
Turkey/H Bm, 43,1991–94
Broth microdilution (MH-P/
5,105-6cfu,0%,35°C,48 h) >16 2->16 [11]
Spain/H Bm, 160,1997
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 1 0.25-1 [25]
Korea/C Bab, 85,1998–2006
Broth microdilution (TSB, 0.5
McFd, 5%, 37°C, 48 h) 1 0.25-4 [19]
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Antibiotics Country/host
Collected
isolates:
species, n,
period£
Method$ (medium, inoculum,
%CO2
temperature and hours of
incubation)
MIC90
(mg/L)
MIC ranges
(mg/L) Reference
Greece/HA Bru, 74,1999–2005
E-test (SB-MH, 0.5 McFd, 5%,
35°C, 48 h) 0.5 0.016-0.75 [16]
Egypt/H Bm, 355,1999–2007
E-test (SB-MH, 0.5 McFd, 5%,
NA, 48 h) 0.38 0.125-0.75 [22]
Peru/H Bm, 48,2000–06
E-test (SB-MH, 0.5 McFd, NA,
NA, 48 h) 0.25 0.064-0.25 [28]
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C,48 h) 0.38 0.064-0.5 [29]
Syria Bm, 100,2004–07
Broth microdilution (BB/7, 5 ×
106 cfu/mL,37°C, 48 h) 4 0.125-8 [15]
Syria Bm, 100,2004–07
Broth microdilution (BB/5, 5 ×
106 cfu/mL,37°C, 48 h) 8 0.125-8 [15]
Italy/H Bru, 20,2005–06
E-test (SB-MH, 0.5 McFd, 5%,
37°C, 48 h) ND 0.094-0.5 [21]
Turkey/H Bm, 73,2009–11
E-test (SB-MH, 0.5 McFd, NA,
37°C, 48 h) 0.19 0.125-1 [26]
Sparfloxacin Israel/H Bm, 86,(1991)
Broth microdilution (BB, 5 ×
105cfu/mL,5%,37°C,48 h) 1.5 NA [33]
Moxifloxacin Spain/H Bm, 160,1997
Agar dilution (MH-HP,104cfu/
spot,10%,35°C,48 h) 1 1 [25]
Turkey/H Bm, 76,2001–06
E-test (SB-MH, 1 McFd, 0%,
35°C,48 h) 0.25 0.032-0.25 [29]
NA, data not available; Bm, B. melitensis; Bab, B. abortus; Bru, Brucella sp.
£Studies have been classified according to the period of isolation of the studied Brucella strains (e.g., 2010–12) and the date
of the corresponding publication (e.g., 1993) when the latter was unavailable.
*TMP/SMX: cotrimoxazole, trimethoprim plus sulfamethoxazole combination at 1/19 ratio, or 1/20 for reference [19] and
1/5 for reference [17].
$Method: Kirby–Bauer disk diffusion method (Kirby-Bauer); E-test strip method (E-test);
Medium: Mueller Hinton agar with 5% sheep blood (SB-MH) or unspecified percentage and type of blood (BA-MH); 5%
sheep blood agar (SB); Brucella broth (BB); Brucella agar (BA); Trypticase soy broth (TSB); Iso-Sensitest® Agar CM47L
(CM47L); Mueller Hinton broth supplemented with 1% polyvitex with (HP) or without (P) 1% hemoglobin, at pH 7 (/7)
or pH 5 (/5); The bacterial inoculum used for antibiotic susceptibility testing is specified in cfu/mL or according to
McFarland standards (McFd). Host: human (H), cattle (C), unspecified or various animals (A).
Table 2. Antibiotic susceptibilities of Brucella sp. to β-lactams, cotrimoxazole, chloramphenicol, macrolides, and
fluoroquinolones, as determined in cell-free media.
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MICs determined for chloramphenicol were not consistent from one study to the other (Table
2): MICs ranged from 0.3 to higher than 100 [9], 0.25 to 4 mg/L [18], and 0.15 to 12.5 mg/L [19].
However, this antibiotic was globally considered poorly effective in vitro against Brucella spp.
The macrolides also display poor in vitro activity against these bacteria (Table 2). MICs to
erythromycin ranged from 0.2 to 16 mg/L using the agar dilution method [30], 0.5 to 8 mg/L
using the E-test method [16], and 0.02 to 256 mg/L using various broth microdilution methods
[9,11,18,19]. However, the very high MICs found in some studies could be related to the use
of a high bacterial inoculum, especially at acidic pH [11]. Azithromycin displayed similar MIC
ranges: 0.03–4 mg/L with the agar dilution method [30,32], 0.06–16 mg/L with the E-test method
[26,28], and <0.12–4 mg/L with the broth microdilution method [11,31], with a deleterious effect
of acidic pH [11].
In recent years, the fluoroquinolones proved to be very active against Brucella spp. in vitro
(Table 2). Ciprofloxacin remains the most effective compound. MICs ranged from 0.12 to 1 mg/
L using the agar dilution method [23,25], 0.016 to 1 mg/L with the E-test method [16,21,22,26,
28,29], and <0.12 to 8 mg/L with the broth dilution method [11,13,19,33]. However, Garcia-
Rodriguez et al. [14] demonstrated that MICs of several fluoroquinolone compounds (includ‐
ing ciprofloxacin), against B. melitensis and B. abortus strains, could be increased up to fourfold
at acidic pH and/or in the presence of high bacterial loads. These authors also showed higher
susceptibility to fluoroquinolones of B. melitensis compared to B. abortus [14].
2.1.2. Bactericidal activity by class of antibiotics
The bactericidal activity of antibiotics against Brucella species has been evaluated by determi‐
nation of the minimal bactericidal concentrations (MBCs) and by kill-time experiments (Table
3). However, various methodologies and definitions for bactericidal activity were used in
different studies. Results greatly varied according to experimental conditions, including the
tested bacterial inoculum and pH of the culture medium [14]. De Rycke et al. [34] reported
higher bactericidal activity of rifampicin compared to tetracycline against B. suis. Assuming
that a bactericidal effect is at least 3-log reduction of the initial bacterial inoculum within 24–
48 h incubation for Brucella sp., a bactericidal activity was reported by Mateu-de-Antonio et
al. [35] at concentrations ranging from two to four times the MIC for the aminoglycosides
(streptomycin and gentamicin), rifampicin, and the fluoroquinolone (enrofloxacin), but not for
the tetracyclines (doxycycline) and the macrolides (erythromycin, clarithromycin, and
roxithromycin). Only the aminoglycosides displayed early bactericidal activity (i.e., within 24
h of incubation) against Brucella sp. [33]. Garcia-Rodriguez et al. [14] reported lack of bacteri‐
cidal activity of fluoroquinolones against 21 strains of B. melitensis, with ciprofloxacin MBCs
ranging from 2 to ≥ 8 mg/L at neutral pH, but higher than 8 mg/L at pH 5.
2.1.3. Antibiotic combinations
The checkerboard method is considered the most accurate technique for in vitro evaluation of
the activity of antibiotic combinations against bacteria. Results are usually expressed as the
sum of fractional inhibitory concentrations (ΣFIC), which is the sum of the ratio of MIC of each
Updates on Brucellosis142
antibiotic used in combination (MICAcomb or MICBcomb) divided by MIC of each antibiotic
(MICA or MICB, for antibiotics A and B, respectively): ΣFIC = MICAcomb/MICA + MICBcomb/MICB.
The antibiotic interactions are considered either synergistic (ΣFIC ≤ 0.5, or ΣFIC ≤ 0.75),
additive (ΣFIC > 0.5 but ≤1, or ΣFIC > 0.75 but ≤1), indifferent (ΣFIC > 1 but ≤2), or antagonistic
(ΣFIC > 2).
Using this method, Mortensen et al. [18] reported a synergistic effect of the combination of
tetracycline with rifampicin, but indifference or antagonism with the combinations of tetra‐
cycline plus either streptomycin or gentamicin. Doxycycline plus rifampicin was reported to
be synergistic in several studies [11,15,35,36]. A synergistic effect was also found for most
Brucella strains tested for the combinations of doxycycline with either streptomycin or
gentamicin [11,35,36]. The rifampicin and streptomycin combination was mainly indifferent
[15]. The combinations of a fluoroquinolone (ofloxacin, ciprofloxacin, or sparfloxacin) with
tetracycline, doxycycline, rifampicin, or streptomycin were mainly indifferent [11,15]. The
rifampicin–azithromycin combination was also mainly indifferent [11], while ciprofloxacin
plus azithromycin combination displayed variable activity (synergistic to antagonistic)
Antibiotic Species Number of
strains
MBC ranges (mg/L) Reference
Doxycycline B. melitensis, B. canis 6 4–>16 [35]
Minocycline B. melitensis, B. canis 6 1–>16 [35]
Gentamicin B. melitensis, B. canis 6 0.25–1 [35]
Streptomycin B. melitensis, B. canis 6 0.25–8 [35]
Ciprofloxacin B. melitensis, B. canis 6 0.5–2 [35]
B. melitensis 21 2–≥8 [14]
Ofloxacin B. melitensis 21 ≥8 [14]
Sparfloxacin B. melitensis 21 2–≥8 [14]
Temafloxacin B. melitensis 21 2–≥8 [14]
Lomefloxacin B. melitensis 21 ≥8 [14]
Fleroxacin B. melitensis 21 ≥8 [14]
Enrofloxacin B. melitensis, B. canis 6 0.25–2 [35]
Rifampin B. melitensis, B. canis 6 0.25–16 [35]
Erythromycin B. melitensis, B. canis 6 2–>16 [35]
Spiramycin B. melitensis, B. canis 6 4–>16 [35]
Clarithromycin B. melitensis, B. canis 6 8–>16 [35]
Roxithromycin B. melitensis, B. canis 6 16–>16 [35]
Table 3. Minimal bactericidal concentrations (MBCs) of several antibiotics against Brucella strains, as determined in
broth culture, at pH 7.
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according to the strains tested [36]. Interestingly, only the combination of doxycycline with
rifampicin retained its synergistic activity at pH 5 [11,15]. It is to be noted also that Rubinstein
et al. [33] did not find any synergistic effect of either of the previously mentioned antibiotic
combinations.
The E-test method has also been used for the evaluation of the activity of antibiotic combina‐
tions [29,37]. Mueller Hinton agar plates supplemented with 5% sheep blood were inoculated
with a 0.5–1 McFarland turbidity standard suspension of Brucella sp. The E-test strips were
then successively applied to the inoculated surface so as MICs overlap at the same position.
The first strip was removed after 1-h incubation, while the second was left on the agar for the
48-h incubation at 35°C. The ΣFIC index was used to interpret results: synergism (ΣFIC ≤ 0.5),
additive (ΣFIC > 0.5 but ≤1), indifference (ΣFIC > 1 but ≤4), and antagonism (ΣFIC > 4).
Sometimes, the additive and indifference categories were combined as indifference. However,
results were not consistent between studies. Ozhak-Baysan et al. [29] reported that, among the
28 Brucella sp. strains tested, the combination of doxycycline with rifampicin was antagonistic
for 25 (89.3%) and indifferent for the remaining three strains. The combination of streptomycin
with rifampicin was synergistic, but only one Brucella strain was tested. Orhan et al. [36] and
Kilic et al. [37] reported two different studies from Turkey, each evaluating antibiotic combi‐
nations against 16 human strains of B. melitensis. A synergistic effect was reported for the
combination of doxycycline with rifampicin for 15/16 (93.7%) strains [36], and for tetracycline
with rifampicin for 16/16 (100%) strains [37]. The combination of doxycycline plus streptomy‐
cin was synergistic for 11/16 (68.7%) strains [36], while doxycycline plus cotrimoxazole was
synergistic for 6/16 (37.5%) strains but antagonistic for the same number of strains [36]. A
synergistic effect was found for the combination of cotrimoxazole with rifampicin for 6/16
(37.5%) strains [36] to 14/16 (87.5%) strains [37]. Ciprofloxacin displayed a synergistic effect
when combined with cotrimoxazole for 7/16 (43.7%) strains [37], or with azithromycin for 12/16
strains (75%) [36]. Tetracycline plus moxifloxacin combination gave a synergistic effect for only
4/16 (25%) strains [37]. The combination of ciprofloxacin with streptomycin was mainly
indifferent [37]. It is to be stressed that Orhan et al. [36] found different results with the same
B. melitensis strains when using the checkerboard technique. The E-test overevaluated the
synergistic effect of most antibiotic combinations compared to the checkerboard technique.
Using kill-time experiments, earlier bactericidal activity was demonstrated with the combi‐
nation of streptomycin with either a tetracycline (tetracycline or doxycycline), rifampicin, or
a fluoroquinolone (including ciprofloxacin) [33,35]. The same was true for the combination of
rifampicin with either a fluoroquinolone (especially ciprofloxacin) or a tetracycline [33]. In
some studies, the combination of rifampicin with a tetracycline was no more effective than the
former antibiotic alone [34]. In contrast, the combination of ciprofloxacin and minocycline was
antagonistic [33].
2.2. AST in eukaryotic cell models
Brucella spp. are facultative intracellular bacteria that infect a number of eukaryotic cells,
including macrophages, dendritic cells, and trophoblasts of the placenta [38]. These bacteria
replicate in acidic endoplasmic reticulum-derived vacuoles. Therefore, in vivo efficacy of
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antibiotics in Brucella-infected hosts is likely dependent on their activity against the intracel‐
lular and extracellular forms of this pathogen. Whereas MICs determined in cell-free media
would allow detection of acquired resistances in specific Brucella strains, they cannot predict
in vivo efficacy of antibiotics on their own. Eukaryotic cell models have been developed to test
the activity of antibiotics against intracellular bacteria, including Brucella species. Mouse
peritoneal macrophages and macrophage cell lines, and human monocyte-derived macro‐
phages and macrophage cell lines (Mono Mac 6), have been most often used. These experi‐
mental models are based on in vitro infection of eukaryotic cells with a specific strain of Brucella
sp., then exposure of infected cell monolayers to an antibiotic, and evaluation of residual
intracellular viable bacteria to assess the antibiotic activity. The latter is usually determined
by colony-forming unit (CFU) counting methodology, but quantitative real-time PCR has been
used as a less fastidious alternative, although it does not differentiate viable from nonviable
bacteria. Major limitations of these models include difficulties in eliminating nonphagocytized
bacteria to ensure proper evaluation of intracellular antibiotic activity, lysis of eukaryotic cells
before CFU determination without altering bacterial viability, and defining the most appro‐
priate experimental conditions (especially the time of antibiotic exposure). Also, these models
do not evaluate the influence of host–pathogen interactions (especially the host immune
response) on intracellular activity of antibiotics.
Richardson et al. [39] first reported that streptomycin (at concentrations up to 50 mg/L) was
not bacteriostatic against B. abortus grown in bovine cell cultures, while this antibiotic was
strongly bactericidal in cell-free media. In contrast, tetracycline displayed the same activity
against intracellular and extracellular bacteria. Streptomycin was no more effective when
using guinea pig monocytes [40]. Filice et al. [41] demonstrated that rifampicin could induce
ultrastructural damages to B. melitensis within mouse peritoneal macrophages. In a more recent
study, using B. abortus strain 2308 and two cell lines (human Mono Mac 6 and J774 murine
macrophages), Valderas et al. [42] demonstrated an intracellular bacteriostatic activity for
tetracycline and doxycycline (at 1×MIC and 4×MIC in Mono Mac 6 and J774 cells, respectively),
for rifampicin (at 0.25×MIC and 1×MIC, respectively), and for ciprofloxacin (at 1×MIC and
4×MIC, respectively). Streptomycin and gentamicin displayed no bacteriostatic activity after
24 h in these cell systems. However, these antibiotics slowly penetrate within eukaryotic cells
and reach significant intracellular concentrations only after 3 days of antibiotic–cell contact
[43]. A weak intracellular bactericidal activity (≤ 1-log reduction of bacterial titers) was found
for rifampicin and ciprofloxacin at 4× and 8× MICs, but not for tetracycline and doxycycline
[42]. Akova et al. [11] previously demonstrated the deleterious effect of acidic pH on activity
of antibiotics against Brucella sp. It may be speculated that most antibiotics lose their bacter‐
iostatic and/or bactericidal activity against intracellular Brucella sp. because these bacteria
multiply in acidic cell compartments.
2.3. Animal models
Several animal models have been developed to study in vivo replication of Brucella sp.,
including mice, rats, guinea pigs, rabbits, and nonhuman primates [44]. The in vivo activity of
antibiotics against this pathogen has been mainly evaluated in mice, rats, and guinea pigs.
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These animals develop persistent bacteremia and a disseminated infection (especially in liver,
spleen, and lungs). However, guinea pigs are the most susceptible animals, while rats usually
do not develop clinical symptoms. The evaluation of in vivo efficacy of antibiotics was primarily
based on their ability to eradicate Brucella from the spleen of treated animals compared to
untreated controls, as determined by numeration of viable bacteria (CFU counts) in spleen
tissue collected at the time of sacrifice of infected animals.
Early studies in guinea pigs demonstrated the in vivo activity of sulfanilamide in pigs infected
with B. melitensis [45]. In OF1 mice and Hartley guinea pigs infected with B. melitensis or B.
suis, rifampicin was able to eradicate bacteria from the spleen of most animals, while only
partial decrease in spleen bacterial loads were observed with tetracycline [34,46]. In a more
recent study, ICR mice were infected with B. melitensis 16M and received various antibiotic
treatments (21 days orally or 14 days intraperitoneally) 7–14 days postinfection [47]. Rifampin
(25 mg/kg/d, ip) and doxycycline (40 mg/kg/d ip) were highly effective to eradicate bacteria
from the spleen, while streptomycin (75 mg/kg/d, ip), cotrimoxazole (15 mg/kg/d of TMP, ip),
and ciprofloxacin (20 mg/kg/d ip) were not. Doxycycline was less effective when administrated
orally at 6–80 mg/kg/d. The same authors later reported a much lower activity of rifampicin
at a lower dosage (3 mg/kg/d), but a synergistic effect of the combination of streptomycin with
either doxycycline or rifampicin [48]. Spiramycin, a macrolide compound, was tested in
Sprague Dawley rats infected with B. melitensis [49]. Spiramycin (50 mg/kg/d, 21 days) alone
or combined with rifampicin (50 mg/kg/d, 21 days) was found as effective as the combination
of doxycycline (40 mg/kg/d, 21 days) with rifampicin. Dirithromycin, another macrolide
compound, was less effective (27.3% cure rate) in mice infected with B. abortus S544 strain, but
highly effective (81.8% cure rate) when combined with rifampicin [50]. In the same model, the
fluoroquinolone levofloxacin was poorly effective when used alone (36.4% cure rate), and no
more effective than rifampicin alone when combined with this antibiotic (72.7% cure rates in
both cases) [50]. In Wistar albino rats infected with B. abortus [51], moxifloxacin (21 days) was
less effective than rifampicin (cure rates in spleen of 50% and 80%, respectively). In mice
infected with B. melitensis [52–54], doxycycline was much more effective to prevent bacterial
multiplication than the fluoroquinolone compounds ciprofloxacin, moxifloxacin, gatifloxacin,
trovafloxacin, and grepafloxacin, when administrated before or within hours after the bacterial
challenge. Doxycycline was also effective to control B. melitensis infection when administrated
7–14 days following infection, whereas all the tested fluoroquinolones were ineffective. In the
same animal model [54], the azalide compound azithromycin was able to control B. meliten‐
sis infection when administrated 2 h following the bacterial challenge. Altogether, the
Brucella-infected animal models confirmed in vivo activity of rifampicin (the most effective
antibiotic in all studies) and doxycycline, administrated alone or in combination. The combi‐
nation of one of these two antibiotics with streptomycin was also effective. In contrast, the
fluoroquinolones, cotrimoxazole, and the macrolides were unable to eradicate Brucella in most
infected animals. A synergistic effect was found for the combination of a macrolide with
rifampicin, but not for that of a fluoroquinolone with rifampicin. It is to be stressed, however,
that these animal models greatly varied according to the animal species used, the Brucella
species tested, the route and inoculum of the bacterial challenge, the dosage and duration of
the tested antibiotic treatments, the time of administration of antibiotics compared to the
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bacterial challenge, and the time of antibiotic treatment evaluation. More standardization is
needed to allow comparison of results obtained in different research laboratories.
The in vivo efficacy of antibiotics to eradicate Brucella has also been evaluated in naturally
infected animals. Radwan et al. [55] reported the eradication of B. melitensis from 480 naturally
infected sheep and goats with the combination of oxytetracycline with streptomycin, as
evidenced by cessation of shedding B. melitensis from udder secretions and absence of this
bacterium in tissues at autopsy after antibiotic treatment.
3. Acquired resistances to antibiotics in Brucella species
In vitro selection of rifampicin-resistant mutants has been reported for B. melitensis, B. abor‐
tus, and B. suis [12,34,56]. In B. suis, the spontaneous rate of mutations leading to rifampicin
resistance was evaluated at 2.5 × 10–9 (for a concentration of 25 mg/L) [34]. Marianelli et al. [56]
characterized the genetic mechanisms involved in resistance to rifampicin in the vaccine strain
B. abortus RB51, and in laboratory mutants derived from two B. melitensis isolates. They found
missense mutations in two regions of the rpoB gene encoding subunit B of RNA polymerase,
the bacterial target of rifampicin. These mutations led to a number of amino acid changes:
Val154Phe, Asp526Tyr, Asp526Gly, Asp526Asn, His536Leu, His536Tyr, Arg539Ser,
Ser541Leu, and Pro574Leu. A number of studies have reported wide ranges of rifampicin MICs
(up to 64 mg/L) in human and animal strains of Brucella sp., with MIC variations between
geographic regions and time periods considered [9,11,15,19,22,23,26,30,33,57,58]. In vivo
selection of rifampicin-resistant mutants was also reported in a patient who relapsed after
treatment with doxycycline and rifampicin [59]. These results have suggested the possibility
of acquired resistance to rifampicin in Brucella species. However, there is currently no clear
characterization of rpoB mutations leading to rifampicin resistance in Brucella strains isolated
from humans or animals. Direct amplification and sequencing of the rpoB gene did not reveal
any rifampicin resistance mutation in two recent studies from Turkey [60] and Spain [61], in
21 and 62 human strains of B. melitensis, respectively.
Very few studies have reported high doxycycline MICs (up to 32 mg/L) in animal and human
strains of Brucella sp. [11,15,17,57]. In some studies, however, high-level MICs may have been
related to the use of a high bacterial inoculum rather than true acquired resistance to tetracy‐
clines [15,17]. Acquired resistance mechanisms to tetracyclines in Brucella strains have never
been characterized in clinical situation, although the gene encoding the tetracycline resistance
protein TetB was found in the genome of B. abortus [62]. The same holds true for the amino‐
glycoside streptomycin, with MICs > 64 mg/L in only two studies [9,15], while high MICs to
gentamicin have not been reported so far. High MICs to trimethoprim–sulfamethoxazole
combination have also been reported [10,13,17,57,58,63,64], but without characterization of the
involved mechanisms. The MICs of macrolides, especially erythromycin [11,16,18,30], are
highly variable among Brucella strains. For either of these antibiotics, no resistance mechanism
has been characterized.
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Fluoroquinolone resistance mechanisms have been characterized in in vitro selected resistant
mutants of B. melitensis and B. abortus [65–67]. The amino acid substitutions Ala87Val and
Asp91Tyr (corresponding to codon positions gyrA83 and gyrA87 in E. coli numbering system)
were reported. However, efflux pump overexpression was also probably involved in fluoro‐
quinolone resistance in Brucella sp. [65,68]. High ciprofloxacin MICs (up to 8 mg/L) have been
reported for human and animal strains of Brucella sp. [11,15,19,30,57]. No gyrA mutation has
been reported so far in these strains [61]. However, overexpression of efflux pumps in Brucella
strains remains difficult to demonstrate, and could partly explain treatment failures observed
with fluoroquinolones in brucellosis patients [61]. RND-type efflux pumps have been charac‐
terized in Brucella sp [69].
4. Correlation between laboratory data and clinical efficacy of antibiotics
In untreated patients, brucellosis may be controlled by the immune system, but relapses and
chronic evolution of the disease are frequently observed [1]. The combination of immune
defenses and an appropriate antibiotic therapy allows earlier amendment of clinical symptoms
and more effective control of infection. The clinical experience regarding the treatment of
brucellosis has established some basic principles that remain true today [70]. To reduce the
risk of recurrence, at least two antibiotics should be administrated for a minimum of 4–6 weeks.
The combination of doxycycline with either rifampicin or an aminoglycoside (streptomycin or
gentamicin) is the most effective in vitro and is considered the first alternative for the treatment
of brucellosis [71]. It is likely that the effectiveness of these antibiotic combinations depends
on their activity on both extracellular and intracellular Brucella, and their ability to reach the
infectious sites and remain active at local conditions (including an acidic pH in eukaryotic cell
compartments, but also in organ abscesses). AST in cell-free media is poorly predictive of the
in vivo activity of antibiotics against Brucella sp. However, these models have shown that the
aminoglycosides and rifampin display significant bactericidal activity against extracellular
Brucella [33,35]. Cell models have shown that rifampicin is the only antibiotic with a bacteri‐
cidal activity against the intracellular form of Brucella, whereas the tetracyclines and the
fluoroquinolones are mainly bacteriostatic [39,42]. The aminoglycosides had no activity
against intracellular Brucella [39,42]. However, their activity was evaluated in Brucella-infected
cell models after 24 h of antibiotic exposure, while these antibiotics significantly penetrate and
concentrate in eukaryotic cells only after 3 days [43]. Thus, in patients treated with an amino‐
glycoside, potential intracellular activity of these antibiotics cannot be ruled out. The animal
models confirmed a clear superiority of rifampicin and doxycycline for eradication of Brucella
sp. from the spleen [34,46,48], while the fluoroquinolones were much less active [50–54].
Altogether, the superiority of the combinations of doxycycline with either an aminoglycoside
or rifampicin in brucellosis patients could be related to the synergistic effect of an extracellular
bactericidal activity (especially using an aminoglycoside or rifampicin) with an intracellular
bactericidal activity (doxycycline or rifampicin, plus an appropriate cell immune response). A
prolonged antibiotic therapy is likely needed because of poor bactericidal activity of antibiotics
against intracellular Brucella and the need for progressive development of an efficient immune
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response. Hence, brucellosis is usually a more severe disease in immunocompromised
patients, often with a chronic evolution [72–74].
Nevertheless, relapse rates of 5%–15% are still reported in immunocompetent patients after
administration of appropriate antibiotic therapy, sometimes several decades following the
primary infection [73,75]. A first explanation could be the lack of eradication of Brucella by
antibiotics in these relapsing patients because of interindividual variability in the inflamma‐
tory and immune responses to Brucella infection. It should be stressed that in animal models,
the eradication rates obtained after antibiotic treatment varied from one animal species to the
other, and between individuals of a same species [47,48,50–54]. Second, the infectious dose
and delay in antibiotic treatment after infection may also greatly influence antibiotic activity.
A typical example concerns the fluoroquinolones which were effective to control Brucella
infection in animal models when administrated before or immediately after the infectious
challenge, but not when administrated 1 or 2 weeks later [47,48,50–54]. Third, in vivo selection
of Brucella mutants, resistant to antibiotics in brucellosis patients under antibiotic therapy,
could also explain the therapeutic failures and relapses, especially for rifampicin and the
fluoroquinolones [59,65–67]. Although in vitro studies have suggested that Brucella sp. could
become resistant to first-line antibiotics used for brucellosis treatment, definite proofs of
selection of acquired resistances in the clinical situation are still lacking. Interestingly, similar
antibiotic susceptibilities were reported in B. melitensis strains isolated before and after
antibiotic therapy in brucellosis patients suffering from relapses [28,76], which indicated that
treatment failure was not related to development of acquired resistances to antibiotics in this
pathogen.
Improving our understanding of treatment failures and relapses in brucellosis patients will
necessitate not only a better standardization of assessment of the antibiotic activity using both
in vitro and in vivo approaches, but also the development of new diagnostic tools to explore
previous hypotheses directly in infected patients.
5. New therapeutic alternatives
5.1. Novel antibiotics
Tigecycline, a glycylcycline compound derived from minocycline, displays broad ranges of
MICs and higher MIC90 in vitro than doxycycline against Brucella sp. [26,27,29,77]. In contrast,
a lower MIC90 was reported for tigecycline (0.125 mg/L) compared to tetracycline (0.25 mg/L)
for 60 strains of B. melitensis [78]. Using the checkerboard method, Aliskan et al. [79] reported
a synergistic effect of the combination of tigecycline with either levofloxacin (50% of the 16
strains tested), rifampicin (31.2%), or gentamicin (18.9%). No synergy was observed with
tigecycline in combination with streptomycin or cotrimoxazole. Dizbay et al. [80] reported a
higher synergistic effect of antibiotic combinations when tigecycline was used compared to
doxycycline. It has been proposed to replace doxycycline by tigecycline in current therapeutic
protocols of brucellosis [81–83]. Although tigecycline could be as effective as doxycycline in
antibiotic combination therapies, there are currently major limitations for its widespread use
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in brucellosis patients. At first, tigecycline is tens of times more expensive than doxycycline.
Second, it can only be administrated by the parenteral route and thus its use would be restricted
to the acute phase of brucellosis and/or in patients hospitalized because of a severe disease.
Third, the antibacterial spectrum of tigecycline is much broader than that of doxycycline,
including staphylococci (especially methicillin-resistant S. aureus), streptococci, enterococci,
some anaerobes, and most enterobacterial species (including those secreting extended
spectrum beta-lactamases), but not species of the Proteae tribe and Pseudomonas aeruginosa [83].
Thus, significant alterations of the skin and gut commensal flora would certainly occur in the
treated population, with an increased risk of opportunistic infections and development of
resistances to the glycylcyclines. Finally, it is not clear if the favorable pharmacokinetic
properties of tigecycline in tissues could lead to a significant reduction in duration of treatment
or relapse rates. Also, as for tetracyclines, tigecycline is contraindicated in pregnant women
and young children.
Among new fluoroquinolones, moxifloxacin did not display higher activity compared to
ciprofloxacin in vitro [25,29,37] or in animal models [51–54]. The use of a triple combination of
doxycycline, rifampicin, and a fluoroquinolone warrants further evaluation, at least for
treatment of severe brucellosis cases such as spondylodiscitis, endocarditis, and neurobrucel‐
losis [84–86].
Among the new macrolide compounds, azithromycin displayed in vitro bacteriostatic activity
against Brucella sp. with MIC90 ranging from 0.5 to 8 mg/L [11,26,28,30–32]. A synergistic effect
was found when this antibiotic was combined with ciprofloxacin [36]. Azithromycin was also
able to control B. melitensis infection in the mouse model [54]. However, azithromycin was
much less effective than doxycycline to cure brucellosis in Swiss-Webster or BALB/c mice [87].
Although the macrolides are currently not considered suitable for treatment of brucellosis,
they could represent a safe alternative in young children and pregnant women. Further
evaluation of the in vitro and in vivo activity of macrolides combined with other antibiotic
classes against Brucella sp. is warranted.
Medicinal plants have been evaluated for their in vitro activity against B. melitensis. Using a
Mueller Hinton broth dilution method, Motamedi et al. [88] reported that ethanolic and
methanolic extracts of six plants displayed anti-Brucella activity: Oliveria decumbens, Salvia
sclarea, Ferulago abgulata, Vitex pseudo-negundo, Teucrium pollium, and Crocus sativus. O.
decumbens was the most effective with similar MICs and MBCs. Al-Mariri and Safi [89]
evaluated the activity of essential oils against 16 Brucella strains. They found a bacteriostatic
effect for essential oils from two medicinal plants: Thymus syriacus and Origanum syriacum.
5.2. Intracellular delivery of antibiotics
The aminoglycosides are able to penetrate eukaryotic cells, albeit very slowly, but concentrate
in the acidic lysosomal compartment because of their weak base nature [43]. At acidic pH,
these antibiotics are partially inactivated because of their protonation. Although intracellular
pharmacokinetic studies were mostly conducted using uninfected eukaryotic cells, it is
tempting to extrapolate these data to Brucella-infected cells. In vitro studies have been per‐
formed to evaluate the influence of increased uptake of aminoglycosides within eukaryotic
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cells on their activity against intracellular Brucella. These antibiotics (especially streptomycin
and gentamicin) were either included in liposomes or attached to nanoparticles. Phagocytosis
of liposomal or nanoparticle formulations of aminoglycosides by Brucella-infected macro‐
phages resulted in higher intracellular activity compared to free aminoglycosides against B.
melitensis, B. abortus, or B. canis [90–94]. These formulations of the aminoglycosides were also
significantly more effective in animal models [90,94,95]. The targeted delivery of aminogly‐
cosides could be a promising therapeutic alternative, both increasing their intracellular activity
and reducing their side effects by reducing their concentration in kidneys and the cochleoves‐
tibular system. However, there are currently technical limitations in the preparation of
liposomal or nanoparticle forms of antibiotics and safety concerns, especially for nanoparticles
that limit their use in humans [96].
5.3. Peptide nucleic acids
Peptide nucleic acids (PNAs) are artificially synthesized polymers similar to DNA or RNA
that can be used as antisense therapies. They show high specificity in binding to complemen‐
tary DNAs, resistance to nucleases and proteases, and a high stability over a wide pH range.
They readily cross the bacterial cell membranes when coupled with a cell-penetrating peptide.
Rajasekaran et al. [97] reported growth inhibition of B. suis by PNAs, both in cell-free medium
and in murine macrophages. In tryptic soy broth, the inhibitory PNAs were those targeting
the genes kdtA (coding for a transferase affecting lipid A), tsf (elongation factor Ts), polA (DNA
polymerase I), and rpoB (subunit B of RNA polymerase). In contrast, in J774A.1 murine
macrophages, the inhibitory PNAs targeted the genes asd (coding for an aspartate-semialde‐
hyde dehydrogenase involved in diaminopimelic acid synthesis), gyrA (subunit A of DNA
gyrase), dnaG (protein primase that initiates DNA replication), and polA. The PNAs were thus
able to penetrate the eukaryotic and bacterial membranes, and could represent new therapeutic
alternatives for intracellular pathogens such as Brucella sp.
5.4. Enhancement of the host response
Multiplication within phagocytic cells is a major virulence factor of Brucella species. The host
response to Brucella infection could be strengthened by restoring the ability of phagocytic cells
to control intracellular multiplication of these bacteria and eradicate them via the phagolyso‐
somal pathway, especially using cytokines. Jiang and Baldwin [98] reported the in vitro
inhibition of B. abortus multiplication in BALB/c J774A.1 murine macrophages by gamma
interferon (IFN-γ) or to a lesser extent interleukin-2 (IL-2, 100 U/mL). In contrast, IL-1α, IL-4,
IL-6, tumor necrosis factor alpha (TNF-α), and granulocyte macrophage–colony-stimulating
factor (GM–CSF) had no significant effect on intracellular growth of B. abortus. The protective
role of IFN-γ was also emphasized by Murphy et al. [99], using IFN-γ gene knockout mice
infected with B. abortus. When adsorbed to albumin nanoparticles, IFN-γ was even more
effective to control B. abortus infection in RAW 264.7 macrophages and BALB/c mice [100].
Fahel et al. [101] recently reported in a mouse model of B. abortus infection that a higher host
resistance to infection was associated with an increased expression of interleukin-12 (IL-12),
gamma interferon (IFN-γ), and inducible nitric oxide synthase (iNOS) during the course of
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infection. This protective Th1 immune response was negatively regulated by 5-Lipooxygenase
(5-LO), an enzyme required for the production of the lipid mediators leukotrienes and lipoxins.
The use of interferon-gamma has never been reported so far in brucellosis patients.
6. Conclusion
Brucellosis remains a prevalent disease in the world, a major concern in public health and an
economic burden in agriculture. Although effective vaccines are available for the livestock,
treatment of brucellosis remains challenging in both animals and humans. Recommendations
for treatment of common clinical forms of human brucellosis have been addressed, especially
by the WHO. However, treatment optimization is still needed for severe forms of the disease
and in young children and pregnant women. Moreover, current treatment recommendations
could be challenged by the emergence of acquired resistances to first-line drugs in Brucella
species, although this fear needs to be confirmed with certainty in the clinical situation.
Alternative therapeutic options are needed to reduce the human and economic costs associated
with this disease. This could be achieved through the development of new molecules but also
by an optimized use of currently available antibiotics. However, controlling Brucella infection
in the livestock remains a priority.
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